New combo attack on brain tumors: electric fields, laser, and immunotherapy
NCT ID NCT06558214
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the safety and feasibility of combining three treatments—tumor-treating electric fields (Optune GIO), MRI-guided laser ablation (NeuroBlate), and the immunotherapy drug pembrolizumab (Keytruda)—in 20 adults with recurrent glioblastoma. Participants receive the triple combination, and researchers monitor for severe side effects and how well the treatment can be delivered. The goal is to see if this aggressive approach is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda), Tumor Treating Fields (Optune GIO), and laser ablation (NeuroBlate)
What this could lead to
If successful, this combination could offer a new treatment option for recurrent glioblastoma, potentially improving survival and quality of life.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The triple therapy may cause serious side effects or fail to control tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UF Health Shands Hospital
RECRUITINGGainesville, Florida, 32608, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••